1. Whole-brain Irradiation Field Design: A Comparison of Parotid Dose
- Author
-
Steven R. Isaacson, M.E. Lapa, Heva J. Saadatmand, Anurag Saraf, Jacquelyn I.S. Andrew, Yen-Ruh Wuu, Ashish Jani, Cheng-Chia Wu, Akhil Tiwari, Tony J. C. Wang, C.H. Tai, and Simon K. Cheng
- Subjects
Organs at Risk ,medicine.medical_treatment ,Sensitivity and Specificity ,Effective dose (radiation) ,Dose constraints ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Radiation Protection ,0302 clinical medicine ,stomatognathic system ,medicine ,Humans ,Parotid Gland ,Radiology, Nuclear Medicine and imaging ,In patient ,Single institution ,Retrospective Studies ,Radiological and Ultrasound Technology ,Brain Neoplasms ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Radiation field ,Reproducibility of Results ,Radiotherapy Dosage ,Whole brain irradiation ,Radiation Exposure ,medicine.disease ,Radiation therapy ,stomatognathic diseases ,Oncology ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,Cranial Irradiation ,business ,Nuclear medicine - Abstract
Whole-brain radiation therapy (WBRT) plays an important role in patients with diffusely metastatic intracranial disease. Whether the extent of the radiation field design to C1 or C2 affects parotid dose and risk for developing xerostomia is unknown. The goal of this study is to examine the parotid dose based off of the inferior extent of WBRT field to either C1 or C2. Patients treated with WBRT with either 30 Gy or 37.5 Gy from 2011 to 2014 at a single institution were examined. Parotid dose constraints were compared with Radiation Therapy Oncology Group (RTOG) 0615 nasopharyngeal carcinoma for a 33-fraction treatment: mean
- Published
- 2017